Vieworks (100120 KQ/Buy)Steady Performance, Attractive Valuation
For 4Q25, Vieworks reported revenue of W68.6bn (+15% YoY) and operating profit of W8.5bn (OP margin of 12%, +23% YoY), with both figures meeting...
146 Views
Korean Share Buybacks in the Time of Coronavirus
There has been a surge in the number of share buybacks in Korea in the past week as a result of the significant recent decline in the stock...
554 Views
MediSetter Interview:Â Insight on Opportunities in Asia's Healthcare Industry
Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...
4.2k Views
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.6k Views
Genoray IPO Preview (Part 2) - Valuation Analysis
We are positive on the Genoray IPO. Our one year price target of the company is 25,944 won, which would represent nearly 27% higher than the high...
384 Views